2+ day, 16+ hour ago   (80+ words) Sept 11 (Reuters) - ​The ‌U.S. Food and ‌Drug ​Administration ⁠on ⁠Friday approved Scholar ​Rock's ⁠therapy ⁠to ​treat ​a rare genetic ‌condition ⁠that causes muscle ⁠weakness. (Reporting ‌by ⁠Sneha ​S ‌K in ​Bengaluru; ⁠Editing by Tasim ​Zahid)... US FDA approves Scholar…...

2+ day, 16+ hour ago   (77+ words) Sept 11 (Reuters) - ​AstraZeneca ‌said on Friday ‌its ​breast ⁠cancer ⁠drug failed ​to ⁠meet ⁠the main ​goal ​of improving ‌progression-free survival ⁠during a late-stage ⁠trial. (Reporting ‌by ⁠Christy ​Santhosh ‌in ​Bengaluru; ⁠Editing by Tasim ​Zah... Astrazeneca’s breast cancer drug fails late-stage…...

4+ day, 2+ hour ago   (278+ words) Sept 10 (Reuters) – Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental ​epilepsy drug after rodent findings, sending its shares ‌down more than 13% in premarket trading. Here are…...

5+ day, 2+ hour ago   (872+ words) Sept 9 (Reuters) – Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona. A drug being developed by AstraZeneca significantly reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, researchers reported on…...

5+ day, 20+ hour ago   (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat ‌rare disease. Dyne’s stock led declines…...

6+ day, 1+ hour ago   (249+ words) Sept 8 (Reuters) – Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting the main ​goal of a late-stage trial. Shares of the ‌company were up over 25% in premarket trading. • Hereditary angioedema causes…...

6+ day, 1+ hour ago   (257+ words) Sept 8 (Reuters) – Bristol Myers Squibb said on Tuesday its experimental cell therapy showed a high overall response rate in a mid-stage trial, ​in patients with a hard-to-treat form of ‌blood cancer. The study evaluated the therapy, called arlocabtagene autoleucel, or…...

6+ day, 7+ hour ago   (176+ words) ZURICH, Sept 8 (Reuters) – Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran’s ​impact on myotonic dystrophy, a form ‌of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030. Novartis…...

6+ day, 9+ hour ago   (652+ words) NEW DELHI, Sept 8 (Reuters) – India is witnessing an unprecedented food safety crackdown, with regulators forcing many local eateries and branded restaurants to suspend operations, while a push for front-of-pack warning labels has rattled the country’s more than $100 billion packaged food…...

1+ week, 2+ hour ago   (191+ words) Sept 7 (Reuters) – Novo Nordisk said on Monday it had halted two additional trials of its ​experimental cardiovascular drug ziltivekimab, further ‌denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. In July, Novo said ziltivekimab failed…...